New cervical cancer screening with light and DNA test
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is testing a new, non-invasive way to screen for cervical cancer. It uses a photoelectric device and an epigenetic test done on a sample from your cervix. The goal is to find early signs of cancer more accurately than current methods.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 65 years old and have had sex.
- You have a positive test for HPV 16 or 18, or a high-risk HPV type with an abnormal Pap result (ASC-US or worse).
- You have never had cervical cancer or cervical procedures like cone biopsy, ablation, or photodynamic therapy.
- You are not currently menstruating, and you have not had sex or used vaginal medicine for 48 hours before the screening.
- You cannot have a severe immune system problem, a bleeding disorder, or a condition that makes you sensitive to light.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new light-based device to screen for cervical cancer. It is for people who already have abnormal screening results (like high-risk HPV and an abnormal Pap test).
This study tests a new technology to help find cervical cancer earlier by focusing on people who already had an abnormal screening result. It may help improve how abnormal tests are checked and diagnosed.
This trial is testing a new, low-cost, lab-free screening test for cervical cancer. The goal is to see if it can detect early signs of cancer without needing a doctor's visit or a lab — making it easier for women to get screened.
This trial tests a personalized blood test that looks for tumor DNA to monitor cervical cancer and help guide treatment decisions. It is for people with advanced or returning cervical cancer who haven't started treatment yet.
This study tests a light-activated therapy (HAL-PDT) to treat high-grade cervical dysplasia before considering surgery. It compares the response to standard surgery, aiming to see if the light therapy can help avoid or delay more invasive procedures.
This study tests ways to improve cervical cancer screening for women ages 30–65. It may help catch cervical cancer early or prevent it entirely by finding precancerous changes.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.